Prices for two dosages of the blood pressure drug valsartan rose more than any other drug in the United States in September, following a recall of much of the drug’s supply.
Chinese pharmaceutical ingredient manufacturer Zhejiang Huahai Pharmaceuticals recalled valsartan from consumers in the United States in July after finding traces of a probable carcinogen.
According to the National Average Drug Acquisition Cost (NADAC) survey for last month, prices for 160 milligram and 80 milligram tablets of the drug more than doubled last month from August rates.
The drug – the generic version of Novartis’ Diovan – has been in shortage since August, according to the U.S. Food and Drug Administration.
It was not immediately clear which manufacturers had increased their prices for the drug. Companies that are still selling versions of the drug include Alembic Pharmaceuticals, Jubilant Pharma, and Mylan NV…